Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial)

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Avallone, Antonio ^a   Piccirillo, Maria Carmela ^a   Delrio, Paolo ^a   Pecori, Biagio ^a   Di Gennaro, Elena ^a   Aloj, Luigi ^a   Tatangelo, Fabiana ^a   D'Angelo, Valentina ^a   Granata, Cinzia ^a   Cavalcanti, Ernesta ^a   Maurea, Nicola ^a   Maiolino, Piera ^a   Bianco, Franco ^a   Montano, Massimo ^a   Silvestro, Lucrezia ^a   Terranova Barberio, Manuela ^a   Roca, Maria Serena ^a   Di Maio, Massimo ^a   Marone, Pietro ^a   Botti, Gerardo ^a   Petrillo, Antonella ^a   Daniele, Gennaro ^a   Lastoria, Secondo ^a   Iaffaioli, Vincenzo R ^a   Romano, Giovanni ^a   Caracò, Corradina ^a   Muto, Paolo ^a   Gallo, Ciro ^b   Perrone, Francesco ^a   Budillon, Alfredo ^a   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

FDG PET; HDAC inhibitors; Preoperative chemo radiotherapy; Rectal cancer; Short course radiotherapy (SCRT); Valproic acid (VPA)

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; FLUORODEOXYGLUCOSE F 18; GLUTATHIONE TRANSFERASE P1; HISTONE; RAD51 PROTEIN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; VALPROIC ACID; VASCULOTROPIN; XRCC1 PROTEIN; XRCC3 PROTEIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER RISK; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; DPD GENE; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOTHELIUM CELL; FATIGUE; FEMALE; GENE; GSTP1 GENE; HEALTH CARE COST; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROTEIN ACETYLATION; QT PROLONGATION; RAD51 GENE; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SHORT COURSE THERAPY; SOMNOLENCE; STEM CELL; TS GENE; TUMOR REGRESSION; XRCC1 GENE; XRCC3 GENE; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; RADIOTHERAPY; RECTAL NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE CARE; RADIOTHERAPY; RECTAL NEOPLASMS; RESEARCH DESIGN; VALPROIC ACID; YOUNG ADULT;

EID: 84920840486     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-875     Document Type: Article

References (63)

1. Budillon A, Di Gennaro E, Bruzzese F, Rocco M, Manzo G, Caraglia M: Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. Recent Pat Anticancer Drug Discov 2007, 2:119-134.
2. Di Gennaro E, Piro G, Chianese MI, Franco R, Di Cintio A, Moccia T, Luciano A, de Ruggiero I, Bruzzese F, Avallone A, Arra C, Budillon A: Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. Br J Cancer 2010, 103:1680-1691. 10.1038/sj.bjc.6605969.
3. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A: HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011, 226:2378-2390. 10.1002/jcp.22574.
4. Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A: Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 2009, 8:3075-3087. 10.1158/1535-7163.MCT-09-0254.
5. Di Gennaro E, Bruzzese F, Pepe S, Leone A, Delrio P, Subbarayan PR, Avallone A, Budillon A: Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther 2009, 8:782-791. 10.4161/cbt.8.9.8118.
6. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA: Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008, 34:206-222. 10.1016/j.ctrv.2007.11.003.
7. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M, Cantu D, Gonzalez-Fierro A, Garcia-Lopez P, Zambrano P, Perez-Plasencia C, Cabrera G, Trejo-Becerril C, Angeles E, Duenas-Gonzalez A: Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 2005, 4:22. 10.1186/1476-4598-4-22.
8. Arce C, Perez-Plasencia C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Revilla-Vazquez A, Chavez-Blanco A, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Bargallo E, Villarreal P, Ramírez T, Vela T, Candelaria M, Camargo MF, Robles E, Dueñas-González A: A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 2006, 1:e98. 10.1371/journal.pone.0000098.
9. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D: Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009, 15:2488-2496. 10.1158/1078-0432.CCR-08-1930.
10. Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A: Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007, 25:1979-1985. 10.1200/JCO.2006.08.6165.
11. Chateauvieux S, Morceau F, Dicato M, Diederich M: Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010, 2010:1-18.
12. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hovelmann S, Gottlicher M, Knuth A, Jager E: Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007, 97:177-182. 10.1038/sj.bjc.6603851.
13. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R: FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252. 10.1634/theoncologist.12-10-1247.
14. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002, 8:718-728.
15. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR: A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105:959-967.
16. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, Farra Y, Young D, Grever M: Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006, 12:3997-4003. 10.1158/1078-0432.CCR-05-2689.
17. Rowinsky E, de Bono J, Deangelo D, van Oosterom A, Morganroth J, Laird G, Dugan M, Scott JW, Ottman O: Cardiac monitoring in phase 1 trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies. In Journal of Clinical Oncology, Annual meeting Proocedings. Orlando (FL, USA): ASCO; 2005.
18. Camphausen K, Tofilon PJ: Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007, 25:4051-4056. 10.1200/JCO.2007.11.6202.
19. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K: Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 2010, 11:459-464. 10.1016/S1470-2045(10)70058-9.
20. Su JM, Li XN, Thompson P, Ou CN, Ingle AM, Russell H, Lau CC, Adamson PC, Blaney SM: Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res 2011, 17:589-597. 10.1158/1078-0432.CCR-10-0738.
21. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R: Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011, 77:1156-1164. 10.1212/WNL.0b013e31822f02e1.
22. Di Gennaro E, Pecori B, Terranova Barberio M, Imbimbo S, Zotti A, Bruzzese F, Piccirillo M, Avallone A, Munto P, Budillon A: Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in breast and colorectal cancer cells. In Abstract no 2233. Amsterdam: ECCO-ESMO-ESTRO; 2013.
23. Glynne-Jones R, Kronfli M: Locally advanced rectal cancer: a comparison of management strategies. Drugs 2011, 71:1153-1177. 10.2165/11591330-000000000-00000.
24. Avallone A, Aloj L, Delrio P, Pecori B, Leone A, Tatangelo F, Perri F, Petrillo A, Scott N, Budillon A: Multidisciplinary approach to rectal cancer: Are we ready for selective treatment strategies? Anticancer Agents Med Chem 2013, 13:852-860. 10.2174/18715206113139990123.
25. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM: Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004, 22:1785-1796. 10.1200/JCO.2004.08.173.
26. Nagtegaal ID, Quirke P: What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008, 26:303-312. 10.1200/JCO.2007.12.7027.
27. Nagtegaal ID, van de Velde CJ, Marijnen CA, van Krieken JH, Quirke P: Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol 2005, 23:9257-9264. 10.1200/JCO.2005.02.9231.
28. Guillem JG, Diaz-Gonzalez JA, Minsky BD, Valentini V, Jeong SY, Rodriguez-Bigas MA, Coco C, Leon R, Hernandez-Lizoain JL, Aristu JJ, Riedel ER, Nitti D, Wong WD, Pucciarelli S: cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008, 26:368-373. 10.1200/JCO.2007.13.5434.
29. Rengan R, Paty P, Wong WD, Guillem J, Weiser M, Temple L, Saltz L, Minsky BD: Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection? J Clin Oncol 2005, 23:4905-4912. 10.1200/JCO.2005.10.041.
30. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW: van de Velde CJ; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer . N Engl J Med 2001, 345:638-646. 10.1056/NEJMoa010580.
31. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M: Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009, 373:811-820. 10.1016/S0140-6736(09)60484-0.
32. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24:4620-4625. 10.1200/JCO.2006.06.7629.
33. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355:1114-1123. 10.1056/NEJMoa060829.
34. Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Pahlman L, Wiig JN, Bystrom P, Bujko K, Glimelius B: Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008, 26:3687-3694. 10.1200/JCO.2007.15.3858.
35. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93:1215-1223. 10.1002/bjs.5506.
36. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan SA, McKendrick J, Leong T, Hartopeanu C, Zalcberg J, Mackay J: Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012, 30:3827-3833. 10.1200/JCO.2012.42.9597.
37. Pettersson D, Cedermark B, Holm T, Radu C, Pahlman L, Glimelius B, Martling A: Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010, 97:580-587. 10.1002/bjs.6914.
38. Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crellin A, Kwok-Williams M, Sebag-Montefiore D: Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 2009, 92:210-214. 10.1016/j.radonc.2009.04.007.
39. Radu C, Berglund A, Pahlman L, Glimelius B: Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol 2008, 87:343-349. 10.1016/j.radonc.2007.11.025.
40. Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A: Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg 2012, 99:577-583. 10.1002/bjs.7796.
41. van Dijk TH, Tamas K, Beukema JC, Beets GL, Gelderblom AJ, de Jong KP, Nagtegaal ID, Rutten HJ, van de Velde CJ, Wiggers T, Hospers GA, Havenga K: Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol 2013, 24:1762-1769. 10.1093/annonc/mdt124.
42. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB: Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 2013, 31:2128-2135. 10.1200/JCO.2012.43.7251.
43. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ: HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A 2007, 104:19482-19487. 10.1073/pnas.0707828104.
44. Bertolini F, Shaked Y, Mancuso P, Kerbel RS: The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006, 6:835-845. 10.1038/nrc1971.
45. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994, 73:2680-2686. 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C.
46. Morganroth J, Shah RR, Scott JW: Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval). Clin Pharmacol Ther 2010, 87:166-174. 10.1038/clpt.2009.214.
47. Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G, Meuleman C, Besse B, Boccara F, Kahyat D, Cohen A, Soria JC: Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol 2011, 80:369-379. 10.1016/j.critrevonc.2011.01.009.
48. Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17:1471-1474. 10.1245/s10434-010-0985-4.
49. Chen CC, Lee RC, Lin JK, Wang LW, Yang SH: How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy? Dis Colon Rectum 2005, 48:722-728. 10.1007/s10350-004-0851-1.
50. Huh JW, Park YA, Jung EJ, Lee KY, Sohn SK: Accuracy of endorectal ultrasonography and computed tomography for restaging rectal cancer after preoperative chemoradiation. J Am Coll Surg 2008, 207:7-12. 10.1016/j.jamcollsurg.2008.01.002.
51. Kubota K: From tumor biology to clinical pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001, 15:471-486. 10.1007/BF02988499.
52. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL: Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003, 21:1285-1292. 10.1200/JCO.2003.07.054.
53. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, Werner M, Dose J, Janicke F, Graeff H, Schwaiger M: Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000, 18:1689-1695.
54. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001, 19:3058-3065.
55. Calvo FA, Domper M, Matute R, Martinez-Lazaro R, Arranz JA, Desco M, Alvarez E, Carreras JL: 18 F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004, 58:528-535. 10.1016/j.ijrobp.2003.09.058.
56. Cascini GL, Avallone A, Delrio P, Guida C, Tatangelo F, Marone P, Aloj L, De Martinis F, Comella P, Parisi V, Lastoria S: 18 F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 2006, 47:1241-1248.
57. Avallone A, Aloj L, Caraco C, Delrio P, Pecori B, Tatangelo F, Scott N, Casaretti R, Di Gennaro F, Montano M, Silvestro L, Budillon A, Lastoria S: Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. Eur J Nucl Med Mol Imaging 2012, 39:1848-1857. 10.1007/s00259-012-2229-2.
58. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F: The European Organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376. 10.1093/jnci/85.5.365.
59. Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, Johnson CD, Pilkington SA, Arraras J, Ben-Josef E, Pullyblank AM, Fayers P, Blazeby JM, European Organisation for the Research and Treatment of Cancer Quality of Life Group: Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer 2009, 45:3017-3026. 10.1016/j.ejca.2009.08.014.
60. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23:8688-8696. 10.1200/JCO.2005.02.1329.
61. Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, Calvo FA, Garcia-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W Jr, Suárez J, Theodoropoulos G, Biondo S, Beets-Tan RG, Beets GL: Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010, 11:835-844. 10.1016/S1470-2045(10)70172-8.
62. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJ: Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 2012, 30:1770-1776. 10.1200/JCO.2011.39.7901.
63. Yeo SG, Oh JH, Kim DY, Baek JY, Kim SY, Park JW, Kim MJ, Chang HJ, Kim TH, Lee JH, Jang HS, Kim JG, Lee MA, Nam TK: Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01). Int J Radiat Oncol Biol Phys 2012,86(1):34-39.